Trials with VX-770 concluded that the potentiator provided substantial benefit to respiratory function and overall quality of life among CF patients 12 years and older with at least one G551D CFTR allele, a classical class III variant [186]. This evidence concerns the gene CFTR and cystic fibrosis.